Alzheimer's Disease: Clinical Syndromes, Pathology & Biomarkers (UCSF) 59

Added:

Alternative Etiologies: Metabolic, Pathogen, and Vascular Hypotheses

While mainstream clinical neurology heavily emphasizes the amyloid cascade hypothesis and biomarker-based diagnoses (like amyloid/tau PET scans), a growing body of researchers critiques this dominant paradigm. Detractors argue that focusing primarily on amyloid plaques and tau tangles mistakes downstream pathological hallmarks for the actual root causes of Alzheimer's. Alternative theories propose that the disease is driven by other systemic factors. These include the 'Type 3 Diabetes' hypothesis, which views Alzheimer's as a metabolic disorder characterized by brain insulin resistance; the infectious hypothesis, which suggests chronic neuroinflammation is triggered by latent pathogens like herpesviruses or oral bacteria; and vascular models prioritizing blood-brain barrier dysfunction. These alternative perspectives argue that an over-reliance on amyloid-centric biomarkers has led to costly, marginally effective treatments, and that a more holistic approach targeting metabolic health, inflammation, and vascular integrity is necessary for effective prevention and therapy.

Basic neuroanatomy, particularly the structure and function of the hippocampus, cerebral cortex, and neural pathways involved in memory and cognition.
Fundamental concepts of molecular biology and genetics, including how genetic mutations and risk-associated alleles (e.g., APOE) influence protein expression.
The general mechanism of protein misfolding and aggregation, specifically the basic roles of amyloid-beta and tau proteins in neurodegeneration.
Basic principles of medical imaging modalities, such as Magnetic Resonance Imaging (MRI) and Positron Emission Tomography (PET) scanning.
Translational therapeutics and pharmacology, focusing on disease-modifying therapies for Alzheimer's, such as monoclonal antibodies (e.g., lecanemab).
Clinical trial methodology and the integration of fluid (CSF/blood) and imaging biomarkers in drug development pipelines.
The differential diagnosis of non-Alzheimer's dementias, such as Frontotemporal Lobar Degeneration (FTLD), Dementia with Lewy Bodies (DLB), and vascular dementia.
Ethical, psychological, and legal challenges associated with preclinical diagnosis and predictive genetic/biomarker testing in asymptomatic patients.
1.1M views9Klikes1:27:27@uctvOriginal Release: 2019-07-27

Alzheimer's disease, the most common neurodegenerative disorder worldwide, presents through four distinct clinical syndromes—memory syndrome (hippocampal involvement), visual-spatial syndrome (posterior cortical atrophy), language syndrome (logopenic variant), and frontal/executive syndrome—each reflecting different patterns of brain pathology; the disease progresses through stages from asymptomatic to mild cognitive impairment to dementia, with modern biomarkers including cerebrospinal fluid analysis and PET scans for amyloid and tau detection enabling earlier and more accurate diagnosis.